MedTrace Logo

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04076462 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-04-25

No results posted yet for this study

Summary

The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

Conditions

Interventions

DRUG

CAM2029 (octreotide subcutaneous depot)

Octreotide subcutaneous depot for monthly injections in acromegaly patients

DRUG

Matching placebo

Matching placebo for CAM2029

Sponsors & Collaborators

  • Camurus AB

    lead INDUSTRY

Principal Investigators

  • Pamela Freda, M.D · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-19
Primary Completion
2023-05-02
Completion
2023-05-02
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Greece
  • Hungary
  • Italy
  • Poland
  • Russia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076462 on ClinicalTrials.gov